Posters and Publications

This page is intended to provide scientific information to scientific research professionals. Gossamer Bio’s drug candidates are investigational medicines and have not been approved by The United States Food and Drug Administration (USFDA), Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.

Seralutinib (GB002)

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial

ATS - May 2023

TORREY TLR PLS

ATS - May 2023

GB7208

A CNS-Penetrant BTK Inhibitor Modulates Multiple Pathogenic Pathways Implicated in Multiple Sclerosis

ACTRIMS - Feb 2023

GB7208 is a CNS-Penetrant BTK Inhibitor Demonstrating Potent Activity on Pathogenic Pathways Implicated in Multiple Sclerosis

ECTRIMS1 – October 2022

Discovery Programs

Diacylglycerol Kinase Alpha and Zeta Dual Inhibitors Enhance T Cell Responses and Promote Robust and Durable Anti-Tumor T Cell Immunity

SITC - November 2022

An Orally Bioavailable ENPP1-Selective Inhibitor Demonstrates Superior Immune Preservation Effects Over STING Agonists and Confers Anti-Tumor Efficacy in Combination With Other Therapies in Syngeneic Tumor Models

ENA - October 2022

Seralutinib (GB002)

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial

TORREY TLR PLS

Real-World Referral Patterns of PAH Patients to PHA-Accredited Comprehensive Care Centers in the State of Texas 2019-2020

Quantitative Immunohistochemistry of PDGFRα, PDGFRβ, c-KIT and CSF1R in Human PAH Lung Samples

Phase 1 Drug-Drug Interaction Studies of Inhaled Seralutinib in Healthy Subjects

A phase 1, open-label study of inhaled seralutinib to assess potential effects on the pharmacokinetics (PK) of cytochrome P450 (CYP) and transporter substrates in healthy subjects

Evidence of Target Engagement and Modulation: Biomarker Analysis of the Phase 1b Inhaled Seralutinib Study

Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension

Understanding Drivers and Barriers to Participation in Clinical Trials for Patients With Pulmonary Arterial Hypertension (PAH)

Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension

A targeted approach to the proliferation, fibrosis, and inflammation associated with Pulmonary Arterial Hypertension

TORREY, a Phase 2 Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Functional Class and Physician-Perceived Severity are Similar in Treated and Untreated Patients with Pulmonary Arterial Hypertension: A Real-World Survey

Piecing Together the Future of Pulmonary Arterial Hypertension (PAH)

Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension

A Phase 1b, Multi-center, Randomized, Placebo-controlled Trial of Inhaled Seralutinib in Subjects with WHO Group 1 Pulmonary Arterial Hypertension

Evidence of target engagement and pathway modulation: biomarker analysis of the phase 1b inhaled seralutinib study

A Phase 1B, Multi-Center, Randomized, Placebo-Controlled Trial of Inhaled Seralutinib in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled GB002 for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension

Pharmacologic Characterization of GB002, a Novel Inhaled PDGFR Kinase Inhibitor in Development for Pulmonary Arterial Hypertension (PAH)

Phase 1a Randomized Double-Blind Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Studies of Orally Inhaled GB002 in Healthy Adult Subjects

Clinical Development of Inhaled GB002 for the Treatment of Pulmonary Arterial Hypertension

In Vivo Efficacy of a novel, inhaled PDGFRα/β inhibitor, GB002, in the Rat Monocrotaline and Pneumonectomy Model of Pulmonary Arterial Hypertension

GB002, a Novel Inhaled PDGFR Kinase Inhibitor, Demonstrates Efficacy in the SU5416 Hypoxia Rat Model of PAH

GB7208

A CNS-Penetrant BTK Inhibitor Modulates Multiple Pathogenic Pathways Implicated in Multiple Sclerosis

GB7208 is a CNS-Penetrant BTK Inhibitor Demonstrating Potent Activity on Pathogenic Pathways Implicated in Multiple Sclerosis

GB7208 is a Novel, Highly Potent and Selective CNS-Penetrant BTK Inhibitor for Neuroinflammatory and Neurodegenerative Diseases

Discovery Programs

Diacylglycerol Kinase Alpha and Zeta Dual Inhibitors Enhance T Cell Responses and Promote Robust and Durable Anti-Tumor T Cell Immunity

An Orally Bioavailable ENPP1-Selective Inhibitor Demonstrates Superior Immune Preservation Effects Over STING Agonists and Confers Anti-Tumor Efficacy in Combination With Other Therapies in Syngeneic Tumor Models

Identification of novel inhibitor(s) targeting NLRP3 inflammasome activation

Screening of Small Molecule Libraries for Identification of a Novel Inhibitor of ADAR1

Seralutinib (GB002) – Pulmonary Arterial Hypertension

clinical trials

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

recent posters and publications

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial

TORREY TLR PLS

Seralutinib (GB002) –
Pulmonary Arterial Hypertension